louisakewell, Author at European Medical Journal - Page 22 of 153

The Italian Institutes for Research and Care (IRCCS) Network of Neuroscience and Neurorehabilitation: The Italian Platform for Care and Research About Neurodegenerative Disorders

The Network of Neuroscience and Neurorehabilitation involves 24 highly specialised Italian Institutes for Research and Care (IRCCS) and is focussed on…

Aura and Important Prodrome Symptoms of Migraine: A Study in a Greek Population

Migraine is a common disabling primary headache disorder with two major types: with or without aura. Migraine without aura is a clinical syndrome…

Efficacy of Training in a Virtual Environment for Patients with Balance Disturbances

For many years, force platforms and centre of pressure biofeedback were used as tools for static balance training. However, thanks to motion tracking…

Trazodone in Dravet Syndrome

Dravet syndrome (DS) is an epileptic encephalopathy most commonly associated with SCN1A mutations and is typically refractory to antiepileptic drugs (AED).

Treating Rheumatoid Arthritis to Target: Is Low Disease Activity Good Enough?

Treat-to-target principles in rheumatoid arthritis (RA) are now widely recognised as effective in achieving optimal disease outcomes. This study examined…

Anti-TNF in Rheumatic Diseases: Inventory and Outlook

With an increasing number of biosimilars receiving regulatory approval, the treatment landscape for rheumatic diseases is evolving. Healthcare…

Review of the 19th European League Against Rheumatology Congress 2018

Almost 20 years have passed since the first annual European League Against Rheumatism (EULAR) Congress took place on the sunny shores of the French…

Physician Global Assessments for Disease Activity in Rheumatoid Arthritis Are All Over the Map!

There have been many studies about patient global assessments of disease activity in rheumatoid arthritis (RA) and how these differ from physician global…

Editor's Pick: JAK Inhibitors in the Treatment Algorithm of Rheumatoid Arthritis: A Review

Biological disease-modifying antirheumatic drugs have defined a new era in rheumatoid arthritis (RA) management but share the limitation of antagonising…

Congress Feature from EULAR 2018

Building on last year’s launch, the EULAR ‘Don’t Delay, Connect Today’ campaign was a highlight of this year’s EULAR Congress. As part of EMJ’s…